{"entity":{"id":"nct04068103","kind":"trial","name":"Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery","aka":[],"tldr":"A phase 2/3 trial of capecitabine, fluorouracil (5-FU), fOLFOX (5-FU, leucovorin, oxaliplatin) and leucovorin (folinic acid) in colorectal cancer, run by NRG Oncology, active but no longer recruiting.","summary":"Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery is a phase 2/3, randomised interventional study registered as NCT04068103 by NRG Oncology, with a registry enrolment figure of 635 participants, started 2019-12-16 and due to reach its primary completion in 2023-06-30. Interventions recorded: Capecitabine; Fluorouracil; Leucovorin; Leucovorin Calcium; Oxaliplatin; Patient Observation. Conditions listed: Colon Adenocarcinoma; Stage IIA Colon Cancer AJCC v8. Primary outcome: Clearance of Circulating Tumor Deoxyribonucleic Acid (ctDNA) (to Undetectable Levels) for the \"Baseline ctDNA Detected\" Patient Subset (Phase II); Recurrence-free Survival (RFS) the \"Baseline ctDNA Detected\" Patient Subset (Phase III). Colorectal eligibility wording from the registry: \"* Histologically/pathologically confirmed stage IIA adenocarcinoma of the colon (T3, N0, M0) with at least 12 lymph nodes examined at the time of surgical resection\". Sites: Canada, Puerto Rico, United States. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04068103","url":"https://clinicaltrials.gov/study/NCT04068103"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","mrd-testing","platinum"],"targets":[],"drugs":["capecitabine","fluorouracil","folfox","leucovorin"],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04068103","phase":"2/3","setting":"Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)","sponsor":"NRG Oncology","enrolled":635,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04068103/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"}],"company":[{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}